Creasallis

Creasallis is a Cambridge-based biotechnology company developing engineering solutions to improve the efficacy of antibody-based cancer therapies.

Its patented technology modifies antibodies to enhance their penetration into solid tumours, and is designed as a plug-and-play modification compatible with any antibody isotype, including checkpoint inhibitors and antibody-drug conjugates.

Creasallis is building its own portfolio of solid tumour antibody therapeutics alongside offering the platform to external drug developers.